Adaptive Biotechnologies Corp (ADPT)vsNovartis AG ADR (NVS)
ADPT
Adaptive Biotechnologies Corp
$24.18
+7.18%
HEALTHCARE · Cap: $3.50B
NVS
Novartis AG ADR
$158.83
-0.25%
HEALTHCARE · Cap: $290.96B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 19091% more annual revenue ($56.69B vs $295.41M). NVS leads profitability with a 22.5% profit margin vs -16.8%. NVS earns a higher WallStSmart Score of 51/100 (C-).
ADPT
Avoid30
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+49.4%
Fair Value
$30.86
Current Price
$24.18
$6.68 discount
Margin of Safety
-70.9%
Fair Value
$92.73
Current Price
$158.83
$66.10 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 35.1% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Trading at 17.8x book value
0.0% earnings growth
ROE of -23.0% — below average capital efficiency
Negative free cash flow — burning cash
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ADPT
The strongest argument for ADPT centers on Revenue Growth. Revenue growth of 35.1% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bear Case : ADPT
The primary concerns for ADPT are Price/Book, EPS Growth, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
ADPT profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.
ADPT carries more volatility with a beta of 2.07 — expect wider price swings.
ADPT is growing revenue faster at 35.1% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 30/100), backed by strong 22.5% margins. ADPT offers better value entry with a 49.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adaptive Biotechnologies Corp
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?